IMETAB-6

Title: An Imaging feasibility study in oestrogen receptor negative MEtastatic breast cancer by Targeting integrin alpha –v Beta 6
Disease site: Breast cancer
Status: Recruiting

Trial Design: Pilot study that aims to determine the feasibility of [18F]-FBA-A20FMDV2-PET CT scans to detect levels of αvβ6 in patients with ER negative avb6-positive metastatic or locally advanced breast cancer.  A combination of factors will be used to determine the feasibility of [18F]-FBA-A20FMDV2 PET CT imaging including visual adequacy of the PET CT image, adequate signal to noise ratio and the ability to evaluate the image differential between the metastatic lesion(s) and normal tissue.

This study stems from research carried out by Prof J. Marshall and his team at Barts Cancer Institute.

Trial details

Chief Investigator: Prof P. Schmid
Scientific Lead: Prof J. Marshall
Trial contact: bci-imetab6@qmul.ac.uk
Sponsor: Queen Mary University of London
Participating countries: UK

Clinical Trial Portfolio

Click here to to see a list of our clinical trials that are currently in set up or those that are open to recruitment.